Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Sign Up to like & getrecommendations! Published in 2019 at "Neurology"
DOI: 10.1212/wnl.0000000000008243
Abstract: Objective To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in… read more here.
Keywords: pml; sid; pml risk; risk ... See more keywords